Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine - MediGene/Virionics

Drug Profile

Human papillomavirus vaccine - MediGene/Virionics

Alternative Names: CVLP tumour vaccine - MediGene/Virionics; HPV-16 L1-E7 chimeric VLP - MediGene/Virionics; Human papillomavirus type 16 L1-E7 chimeric virus-like particle vaccine - MediGene/Virionics; PapViRx

Latest Information Update: 30 Aug 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediGene AG
  • Developer MediGene AG; Virionics
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia

Most Recent Events

  • 11 Mar 2008 Preclinical trials in Cervical intraepithelial neoplasia in USA (unspecified route)
  • 11 Mar 2008 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
  • 04 Apr 2006 Human papillomavirus vaccine licensed to Virionics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top